Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility.

Addiction genetics

Blum K, Hauser M, Fratantonio J, Badgaiyan RD.
PMID: 26807291
Addict Genet. 2015 Jul 01;2(1):1-5. doi: 10.1515/addge-2015-0001. Epub 2015 Aug 28.

The Brain Reward Cascade (BRC) is an interaction of neurotransmitters and their respective genes to control the amount of dopamine released within the brain. Any variations within this pathway, whether genetic or environmental (epigenetic), may result in addictive behaviors...

Cite
Blum K, Hauser M, Fratantonio J, et al. Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addict Genet. 2015;2(1):1-5doi: 10.1515/addge-2015-0001.
Blum, K., Hauser, M., Fratantonio, J., & Badgaiyan, R. D. (2015). Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addiction genetics, 2(1), 1-5. https://doi.org/10.1515/addge-2015-0001
Blum, Kenneth, et al. "Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility." Addiction genetics vol. 2,1 (2015): 1-5. doi: https://doi.org/10.1515/addge-2015-0001
Blum K, Hauser M, Fratantonio J, Badgaiyan RD. Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addict Genet. 2015 Jul 01;2(1):1-5. doi: 10.1515/addge-2015-0001. Epub 2015 Aug 28. PMID: 26807291; PMCID: PMC4720149.
Copy Download .nbib Format: NLM
Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention.

BMJ supportive & palliative care

Lyon ME, Thompkins JD, Fratantoni K, Fraser JL, Schellinger SE, Briggs L, Friebert S, Aoun S, Cheng YI, Wang J.
PMID: 31345846
BMJ Support Palliat Care. 2019 Jul 25; doi: 10.1136/bmjspcare-2019-001766. Epub 2019 Jul 25.

OBJECTIVE: To develop and pilot test a palliative care intervention for family caregivers of children with rare diseases (FAmily-CEntered pediatric Advance Care Planning-Rare (FACE-Rare)).METHODS: FACE-Rare development involved an iterative, family-guided process including review by a Patient and Family Advisory...

Cite
Lyon ME, Thompkins JD, Fratantoni K, et al. Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention. BMJ Support Palliat Care. 2019;doi: 10.1136/bmjspcare-2019-001766.
Lyon, M. E., Thompkins, J. D., Fratantoni, K., Fraser, J. L., Schellinger, S. E., Briggs, L., Friebert, S., Aoun, S., Cheng, Y. I., & Wang, J. (2019). Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention. BMJ supportive & palliative care, . https://doi.org/10.1136/bmjspcare-2019-001766
Lyon, Maureen E, et al. "Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention." BMJ supportive & palliative care vol. (2019). doi: https://doi.org/10.1136/bmjspcare-2019-001766
Lyon ME, Thompkins JD, Fratantoni K, Fraser JL, Schellinger SE, Briggs L, Friebert S, Aoun S, Cheng YI, Wang J. Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention. BMJ Support Palliat Care. 2019 Jul 25; doi: 10.1136/bmjspcare-2019-001766. Epub 2019 Jul 25. PMID: 31345846; PMCID: PMC8040699.
Copy Download .nbib Format: NLM
MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2.

Non-coding RNA

Natarelli L, Parca L, Mazza T, Weber C, Virgili F, Fratantonio D.
PMID: 33670580
Noncoding RNA. 2021 Feb 18;7(1). doi: 10.3390/ncrna7010014.

The respiratory system is one of the most affected targets of SARS-CoV-2. Various therapies have been utilized to counter viral-induced inflammatory complications, with diverse success rates. Pending the distribution of an effective vaccine to the whole population and the...

Cite
Natarelli L, Parca L, Mazza T, et al. MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2. Noncoding RNA. 2021;7(1)doi: 10.3390/ncrna7010014.
Natarelli, L., Parca, L., Mazza, T., Weber, C., Virgili, F., & Fratantonio, D. (2021). MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2. Non-coding RNA, 7(1), . https://doi.org/10.3390/ncrna7010014
Natarelli, Lucia, et al. "MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2." Non-coding RNA vol. 7,1 (2021). doi: https://doi.org/10.3390/ncrna7010014
Natarelli L, Parca L, Mazza T, Weber C, Virgili F, Fratantonio D. MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2. Noncoding RNA. 2021 Feb 18;7(1). doi: 10.3390/ncrna7010014. PMID: 33670580; PMCID: PMC7931055.
Copy Download .nbib Format: NLM
Velocity Measurements in Channel Gas Flows in the Slip Regime by means of Molecular Tagging Velocimetry.

Micromachines

Fratantonio D, Rojas-Cárdenas M, Barrot C, Baldas L, Colin S.
PMID: 32252354
Micromachines (Basel). 2020 Apr 02;11(4). doi: 10.3390/mi11040374.

Direct measurements of the slip velocity in rarefied gas flows produced by local thermodynamic non-equilibrium at the wall represent crucial information for the validation of existing theoretical and numerical models. In this work, molecular tagging velocimetry (MTV) by direct...

Cite
Fratantonio D, Rojas-Cárdenas M, Barrot C, et al. Velocity Measurements in Channel Gas Flows in the Slip Regime by means of Molecular Tagging Velocimetry. Micromachines (Basel). 2020;11(4)doi: 10.3390/mi11040374.
Fratantonio, D., Rojas-Cárdenas, M., Barrot, C., Baldas, L., & Colin, S. (2020). Velocity Measurements in Channel Gas Flows in the Slip Regime by means of Molecular Tagging Velocimetry. Micromachines, 11(4), . https://doi.org/10.3390/mi11040374
Fratantonio, Dominique, et al. "Velocity Measurements in Channel Gas Flows in the Slip Regime by means of Molecular Tagging Velocimetry." Micromachines vol. 11,4 (2020). doi: https://doi.org/10.3390/mi11040374
Fratantonio D, Rojas-Cárdenas M, Barrot C, Baldas L, Colin S. Velocity Measurements in Channel Gas Flows in the Slip Regime by means of Molecular Tagging Velocimetry. Micromachines (Basel). 2020 Apr 02;11(4). doi: 10.3390/mi11040374. PMID: 32252354; PMCID: PMC7230473.
Copy Download .nbib Format: NLM
Glutamine-Derived Aspartate Biosynthesis in Cancer Cells: Role of Mitochondrial Transporters and New Therapeutic Perspectives.

Cancers

Gorgoglione R, Impedovo V, Riley CL, Fratantonio D, Tiziani S, Palmieri L, Dolce V, Fiermonte G.
PMID: 35008407
Cancers (Basel). 2022 Jan 04;14(1). doi: 10.3390/cancers14010245.

Aspartate has a central role in cancer cell metabolism. Aspartate cytosolic availability is crucial for protein and nucleotide biosynthesis as well as for redox homeostasis. Since tumor cells display poor aspartate uptake from the external environment, most of the...

Cite
Gorgoglione R, Impedovo V, Riley CL, et al. Glutamine-Derived Aspartate Biosynthesis in Cancer Cells: Role of Mitochondrial Transporters and New Therapeutic Perspectives. Cancers (Basel). 2022;14(1)doi: 10.3390/cancers14010245.
Gorgoglione, R., Impedovo, V., Riley, C. L., Fratantonio, D., Tiziani, S., Palmieri, L., Dolce, V., & Fiermonte, G. (2022). Glutamine-Derived Aspartate Biosynthesis in Cancer Cells: Role of Mitochondrial Transporters and New Therapeutic Perspectives. Cancers, 14(1), . https://doi.org/10.3390/cancers14010245
Gorgoglione, Ruggiero, et al. "Glutamine-Derived Aspartate Biosynthesis in Cancer Cells: Role of Mitochondrial Transporters and New Therapeutic Perspectives." Cancers vol. 14,1 (2022). doi: https://doi.org/10.3390/cancers14010245
Gorgoglione R, Impedovo V, Riley CL, Fratantonio D, Tiziani S, Palmieri L, Dolce V, Fiermonte G. Glutamine-Derived Aspartate Biosynthesis in Cancer Cells: Role of Mitochondrial Transporters and New Therapeutic Perspectives. Cancers (Basel). 2022 Jan 04;14(1). doi: 10.3390/cancers14010245. PMID: 35008407; PMCID: PMC8750728.
Copy Download .nbib Format: NLM
Diurnal Stability Of Peripapillary Vessel Density And Nerve Fiber Layer Thickness On Optical Coherence Tomography Angiography In Healthy, Ocular Hypertension And Glaucoma Eyes.

Clinical ophthalmology (Auckland, N.Z.)

Bochicchio S, Milani P, Urbini LE, Bulone E, Carmassi L, Fratantonio E, Castegna G, Scotti L, Zambon A, Bergamini F.
PMID: 31571821
Clin Ophthalmol. 2019 Sep 20;13:1823-1832. doi: 10.2147/OPTH.S214877. eCollection 2019.

PURPOSE: By using optical coherence tomography angiography (OCTA), to evaluate diurnal changes of the following parameters: vessel density in the peripapillary area (PP-VD) and in the optic nerve head (ONH-VD); thickness of retinal nerve fibre layer (RNFL) and ganglion...

Cite
Bochicchio S, Milani P, Urbini LE, et al. Diurnal Stability Of Peripapillary Vessel Density And Nerve Fiber Layer Thickness On Optical Coherence Tomography Angiography In Healthy, Ocular Hypertension And Glaucoma Eyes. Clin Ophthalmol. 2019;13:1823-1832doi: 10.2147/OPTH.S214877.
Bochicchio, S., Milani, P., Urbini, L. E., Bulone, E., Carmassi, L., Fratantonio, E., Castegna, G., Scotti, L., Zambon, A., & Bergamini, F. (2019). Diurnal Stability Of Peripapillary Vessel Density And Nerve Fiber Layer Thickness On Optical Coherence Tomography Angiography In Healthy, Ocular Hypertension And Glaucoma Eyes. Clinical ophthalmology (Auckland, N.Z.), 131823-1832. https://doi.org/10.2147/OPTH.S214877
Bochicchio, Sara, et al. "Diurnal Stability Of Peripapillary Vessel Density And Nerve Fiber Layer Thickness On Optical Coherence Tomography Angiography In Healthy, Ocular Hypertension And Glaucoma Eyes." Clinical ophthalmology (Auckland, N.Z.) vol. 13 (2019): 1823-1832. doi: https://doi.org/10.2147/OPTH.S214877
Bochicchio S, Milani P, Urbini LE, Bulone E, Carmassi L, Fratantonio E, Castegna G, Scotti L, Zambon A, Bergamini F. Diurnal Stability Of Peripapillary Vessel Density And Nerve Fiber Layer Thickness On Optical Coherence Tomography Angiography In Healthy, Ocular Hypertension And Glaucoma Eyes. Clin Ophthalmol. 2019 Sep 20;13:1823-1832. doi: 10.2147/OPTH.S214877. eCollection 2019. PMID: 31571821; PMCID: PMC6759873.
Copy Download .nbib Format: NLM
Chronic Pancytopenia due to Centrally Mediated Hypothermia in Two Children with Severe Neurological Impairment.

Children (Basel, Switzerland)

Fratantoni K, Hauer JM.
PMID: 32276361
Children (Basel). 2020 Apr 08;7(4). doi: 10.3390/children7040031.

We report on recurrent pancytopenia over five years in two children with severe impairment of the central nervous system. Assessment by hematology did not identify an etiology, including bone marrow biopsy in one. Both patients had sustained normalized blood...

Cite
Fratantoni K, Hauer JM. Chronic Pancytopenia due to Centrally Mediated Hypothermia in Two Children with Severe Neurological Impairment. Children (Basel). 2020;7(4)doi: 10.3390/children7040031.
Fratantoni, K., & Hauer, J. M. (2020). Chronic Pancytopenia due to Centrally Mediated Hypothermia in Two Children with Severe Neurological Impairment. Children (Basel, Switzerland), 7(4), . https://doi.org/10.3390/children7040031
Fratantoni, Karen, and Hauer, Julie M. "Chronic Pancytopenia due to Centrally Mediated Hypothermia in Two Children with Severe Neurological Impairment." Children (Basel, Switzerland) vol. 7,4 (2020). doi: https://doi.org/10.3390/children7040031
Fratantoni K, Hauer JM. Chronic Pancytopenia due to Centrally Mediated Hypothermia in Two Children with Severe Neurological Impairment. Children (Basel). 2020 Apr 08;7(4). doi: 10.3390/children7040031. PMID: 32276361; PMCID: PMC7230753.
Copy Download .nbib Format: NLM
Aspirin and the prevention of myocardial infarction.

The Western journal of medicine

Walsh PN, Fratantoni J.
PMID: 18748053
West J Med. 1977 Sep;127(3):270.

No abstract available.

Cite
Walsh PN, Fratantoni J. Aspirin and the prevention of myocardial infarction. West J Med. 1977;127(3):270
Walsh, P. N., & Fratantoni, J. (1977). Aspirin and the prevention of myocardial infarction. The Western journal of medicine, 127(3), 270.
Walsh, P N, and Fratantoni, J. "Aspirin and the prevention of myocardial infarction." The Western journal of medicine vol. 127,3 (1977): 270.
Walsh PN, Fratantoni J. Aspirin and the prevention of myocardial infarction. West J Med. 1977 Sep;127(3):270. PMID: 18748053; PMCID: PMC1237809.
Copy Download .nbib Format: NLM
Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?.

Clinical medical reviews and case reports

Blum K, Badgaiyan RD, Demotrovics Z, Fratantonio J, Agan G, Febo M.
PMID: 26225358
Clin Med Rev Case Rep. 2015;2(1). doi: 10.23937/2378-3656/1410018.

No abstract available.

Cite
Blum K, Badgaiyan RD, Demotrovics Z, et al. Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?. Clin Med Rev Case Rep. 2015;2(1)doi: 10.23937/2378-3656/1410018.
Blum, K., Badgaiyan, R. D., Demotrovics, Z., Fratantonio, J., Agan, G., & Febo, M. (2015). Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?. Clinical medical reviews and case reports, 2(1), . https://doi.org/10.23937/2378-3656/1410018
Blum, Kenneth, et al. "Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?." Clinical medical reviews and case reports vol. 2,1 (2015). doi: https://doi.org/10.23937/2378-3656/1410018
Blum K, Badgaiyan RD, Demotrovics Z, Fratantonio J, Agan G, Febo M. Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?. Clin Med Rev Case Rep. 2015;2(1). doi: 10.23937/2378-3656/1410018. PMID: 26225358; PMCID: PMC4516390.
Copy Download .nbib Format: NLM
What is a clinical pharmacologist?.

The New England journal of medicine

Fratantoni JC.
PMID: 5773369
N Engl J Med. 1969 Apr 03;280(14):782-3. doi: 10.1056/nejm196904032801421.

No abstract available.

Cite
Fratantoni JC. What is a clinical pharmacologist?. N Engl J Med. 1969;280(14):782-3doi: 10.1056/nejm196904032801421.
Fratantoni, J. C. (1969). What is a clinical pharmacologist?. The New England journal of medicine, 280(14), 782-3. https://doi.org/10.1056/nejm196904032801421
Fratantoni, J C. "What is a clinical pharmacologist?." The New England journal of medicine vol. 280,14 (1969): 782-3. doi: https://doi.org/10.1056/nejm196904032801421
Fratantoni JC. What is a clinical pharmacologist?. N Engl J Med. 1969 Apr 03;280(14):782-3. doi: 10.1056/nejm196904032801421. PMID: 5773369.
Copy Download .nbib Format: NLM
Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis.

Journal of reward deficiency syndrome

McLaughlin T, Blum K, Oscar-Berman M, Febo M, Demetrovics Z, Agan G, Fratantonio J, Gold MS.
PMID: 26065033
J Reward Defic Syndr. 2015;1(1):24-35. doi: 10.17756/jrds.2015-006.

BACKGROUND: Lucid Dreams are a form of dream life, during which the dreamer may be aware that he/she is dreaming, can stop/re-start the dreams, depending on the pleasantness or unpleasant nature of the dream, and experiences the dream as...

Cite
McLaughlin T, Blum K, Oscar-Berman M, et al. Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis. J Reward Defic Syndr. 2015;1(1):24-35doi: 10.17756/jrds.2015-006.
McLaughlin, T., Blum, K., Oscar-Berman, M., Febo, M., Demetrovics, Z., Agan, G., Fratantonio, J., & Gold, M. S. (2015). Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis. Journal of reward deficiency syndrome, 1(1), 24-35. https://doi.org/10.17756/jrds.2015-006
McLaughlin, Thomas, et al. "Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis." Journal of reward deficiency syndrome vol. 1,1 (2015): 24-35. doi: https://doi.org/10.17756/jrds.2015-006
McLaughlin T, Blum K, Oscar-Berman M, Febo M, Demetrovics Z, Agan G, Fratantonio J, Gold MS. Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis. J Reward Defic Syndr. 2015;1(1):24-35. doi: 10.17756/jrds.2015-006. PMID: 26065033; PMCID: PMC4459746.
Copy Download .nbib Format: NLM
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.

Drug safety

Jain P, McKinnell K, Marino R, Vunnava P, Liles-Burden MA, Desai A, Wenten M, Fratantonio J, Akerman SC, Sullivan MA, Bloomgren G.
PMID: 33258068
Drug Saf. 2021 Mar;44(3):351-359. doi: 10.1007/s40264-020-01020-4. Epub 2020 Nov 30.

INTRODUCTION: After treatment with naltrexone extended-release injectable suspension (XR-NTX), a µ-opioid receptor antagonist, opioid tolerance is reduced from pretreatment baseline. Patients may be vulnerable to opioid overdose if they attempt to override the blockade during treatment, at the end...

Cite
Jain P, McKinnell K, Marino R, et al. Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018. Drug Saf. 2020;44(3):351-359doi: 10.1007/s40264-020-01020-4.
Jain, P., McKinnell, K., Marino, R., Vunnava, P., Liles-Burden, M. A., Desai, A., Wenten, M., Fratantonio, J., Akerman, S. C., Sullivan, M. A., & Bloomgren, G. (2021). Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018. Drug safety, 44(3), 351-359. https://doi.org/10.1007/s40264-020-01020-4
Jain, Priya, et al. "Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018." Drug safety vol. 44,3 (2021): 351-359. doi: https://doi.org/10.1007/s40264-020-01020-4
Jain P, McKinnell K, Marino R, Vunnava P, Liles-Burden MA, Desai A, Wenten M, Fratantonio J, Akerman SC, Sullivan MA, Bloomgren G. Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018. Drug Saf. 2021 Mar;44(3):351-359. doi: 10.1007/s40264-020-01020-4. Epub 2020 Nov 30. PMID: 33258068; PMCID: PMC7892734.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries